Syed Yousuf Zafar, MD

Associate Professor of Medicine
Associate Professor in the Sanford School of Public Policy
Affiliate, Duke Global Health Institute
Member of the Duke Cancer Institute
Member in the Duke Clinical Research Institute
Campus mail Duke Box 3505, Durham, NC 27710
Phone (919) 684-8111
Email address yousuf.zafar@duke.edu

Dr. Zafar is a health services researcher with a focus in improving care delivery for patients with advanced cancer. He has obtained advanced training in health services research and has participated in single-institution, multi-institution and national studies focusing on access to care, cost of care, and comparative effectiveness of care delivery between health systems. His primary area of interest is in the cost of cancer care. He has conducted institutional and national studies on how treatment-related costs impact cancer patients' experience. His current work in this arena is focused on patient preferences regarding cost-related communication and decision-making.

A second field of interest is palliative care. Dr. Zafar has collaborated with national and international palliative care leaders to improve the design and delivery of palliative care in cancer clinical trials. Methodologically, this work has centered around systematic literature reviews, iterative surveys, and prospective clinical trials.

Dr. Zafar is a member of the American Society of Clinical Oncology’s Health Disparities and Clinical Practice Guideline Committees. He is a member of the Alliance for Clinical Trials in Oncology's Health Disparities and Health Outcomes Committees. Dr. Zafar's work has been funded by the American Cancer Society, the HealthWell Foundation, the Duke Cancer Prevention and Control Program, the Duke Clinical Research Institute, and the CALGB Foundation.

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2008
  • Resident, Medicine, University of Cincinnati, 2002 - 2005
  • M.D., University of Toledo, 2002

Publications

Phelan, SM, Griffin, JM, Jackson, GL, Zafar, SY, Hellerstedt, W, Stahre, M, Nelson, D, Zullig, LL, Burgess, DJ, and van Ryn, M. "Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer." Psychooncology 22, no. 1 (January 2013): 65-73.

PMID
21954081
Full Text

Zafar, SY, Peppercorn, JM, Schrag, D, Taylor, DH, Goetzinger, AM, Zhong, X, and Abernethy, AP. "The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience." Oncologist 18, no. 4 (2013): 381-390.

PMID
23442307
Full Text

Uronis, HE, Bendell, JC, Altomare, I, Blobe, GC, Hsu, SD, Morse, MA, Pang, H, Zafar, SY, Conkling, P, Favaro, J, Arrowood, CC, Cushman, SM, Meadows, KL, Brady, JC, Nixon, AB, and Hurwitz, HI. "A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." Oncologist 18, no. 3 (2013): 271-272.

PMID
23485624
Full Text

Phelan, SM, Griffin, JM, Jackson, GL, Zafar, SY, Hellerstedt, W, Stahre, M, Nelson, D, Zullig, LL, Burgess, DJ, and Ryn, MV. "Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer." Psycho-Oncology 22, no. 1 (2013): 65-73.

Full Text

Zafar, SY, Malin, JL, Grambow, SC, Abbott, DH, Kolimaga, JT, Zullig, LL, Weeks, JC, Ayanian, JZ, Kahn, KL, Ganz, PA, Catalano, PJ, West, DW, and Provenzale, D. "Chemotherapy use and patient treatment preferences in advanced colorectal cancer: A prospective cohort study." Cancer 119, no. 4 (2013): 854-862.

Full Text

Zullig, LL, Muiruri, C, Abernethy, A, Weiner, BJ, Bartlett, J, Oneko, O, and Zafar, SY. "Cancer registration needs assessment at a tertiary medical centre in Kilimanjaro, Tanzania." World Health Popul 14, no. 2 (2013): 12-23.

PMID
23713208
Scholars@Duke

Zafar, SY, and Abernethy, AP. "Financial toxicity, Part I: a new name for a growing problem." Oncology (Williston Park, N.Y.) 27, no. 2 (2013): 80-149.

Scholars@Duke

Zafar, SY, and Abernethy, AP. "Financial toxicity, Part II: how can we help with the burden of treatment-related costs?." Oncology (Williston Park, N.Y.) 27, no. 4 (2013): 253-256.

Scholars@Duke

Zafar, SY, Grothey, A, Bekaii-Saab, T, Bendell, J, Sherrill, B, Bennett, L, Mun, Y, Sersch, M, Dalal, D, and Hurwitz, HI. "SURVIVAL AMONG METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A RANDOMIZED CONTROLLED TRIAL (RCT) VS AN OBSERVATIONAL COHORT STUDY (OCS)." September 2012.

Scholars@Duke

Strickler, JH, Starodub, AN, Jia, J, Meadows, KL, Nixon, AB, Dellinger, A, Morse, MA, Uronis, HE, Marcom, PK, Zafar, SY, Haley, ST, and Hurwitz, HI. "Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors." Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251-258.

PMID
22744359
Full Text

Pages